Cue Biopharma, Inc. · NASDAQ:CUE
Cue Biopharma — Investor Presentation (June 2026)
11 slides from Cue Biopharma's investor presentation, Jun 1, 2026
Slide 1: Allergy CUE-221: Novel dual MOA anti-IgE
Allergy CUE-221: Novel dual MOA anti-IgE ©2026 ©2025 ©2026Cue ©2024 Cue CueBiopharma Biopharma C ON FI D E NT I A L D O NO T D I ST R I B U T E 5
Slide 2: Differentiated Science Validated by Consistent Clinical Data
Differentiated Science Validated by Consistent Clinical Data Provides CUE-221 Potential to Outperform Existing And Emerging Anti-IgE Therapies Consistent clinical data Driving next phase of Functionally distinct reinforce benchmark- Advancing toward late- growth through dual MOA setting potential in
Slide 3: Massive Unmet Need in Our Global Beachhead Indication: Food Allergy
There is a Massive Unmet Need in Our Global Beachhead Indication: Food Allergy 1 in 10 1 in 13 adults children 33 million More than half of More than 40% of Americans have food allergies adults with food children with food 51% 42% 377% allergies have allergies have experienced a experienced a severe
Slide 4: Omalizumab and an Omalizumab Biosimilar are the Only FDA-Approved Anti-IgE Therapies
Omalizumab and an Omalizumab Biosimilar are the Only FDA- Approved Anti-IgE Therapies 1,2 Significant Unmet Need Remains • Omalizumab works by neutralizing IgE1 o In IgE mediated food allergy, patients are dosed every 2 to 4 weeks and may require up to 4 injections o Patients with high baseline IgE
Slide 5: CUE-221 is a Functionally Distinct Novel Dual MOA Anti-IgE Therapy
CUE-221 is a Functionally Distinct Novel Dual MOA Anti-IgE Therapy, with Pipeline-in-a-Product Potential Potential Future Indications CSU FOOD ALLERGY ~86mm WW patients ~214mm WW patients CUE-221 Dual mechanism ATOPIC anti-IgE ASTHMA DERMATITIS ~287mm WW patients ~223mm WW patients ALLERGIC ANAPHYLA
Slide 6: CUE-221: Designed for Deeper and Durable IgE Suppression
CUE-221: Designed for Deeper and Durable IgE Suppression Higher binding affinity (picomolar range) and slower dissociation (off-rate) than omalizumab CUE-221 OMALIZUMAB IgE nM 50 IgE nM 25 IgE nM 12.5 IgE nM 50 IgE nM 25 IgE nM 12.5 IgE nM 6.25 IgE nM 3.12 IgE nM 6.25 IgE nM 3.12 160 160 140 140 120
Slide 7: IgE Drives Allergic Disease by Engaging Two Critical Receptors
IgE Drives Allergic Disease by Engaging Two Critical Receptors FcεRI and CD23 (FcεRII) regulate the allergic response Cross-linking the FcεRI receptor leads Membrane bound CD23 suppresses IgE production to allergic reaction when bound by IgE IgE binds to FcεRI receptor on the CD23 receptor regulates
Slide 8: CUE-221's Differentiated IgE Binding Enables Distinct Functional Properties
CUE-221’s Differentiated IgE Binding Enables Distinct Functional Properties, Including Preserved Interaction with CD23-Bound IgE CUE-221 does not block IgE binding to CD23, preserving CD23’s natural regulatory function in high -IgE states CUE-221 UB-221 Omalizumab Anti-IgE: IgE complex 120 100 % Max
Slide 9: CD23 Acts as a Natural Brake on IgE Production in High IgE States
CD23 Acts as a Natural Brake on IgE Production in High IgE States CUE-221 leverages the CD23-mediated IgE downregulation pathway, suppressing IgE mRNA and protein synthesis 1 IgE mRNA IgE protein synthesis 1 µg/mL 10 µg/mL 200 *** ** *** 150 ** ** * 175 125 150 mRNA expression 100 Total IgE (%) 125
Slide 10: P1 SAD: Rapid and Prolonged Single-Dose PD Effect
P1 SAD: Rapid and Prolonged Single-Dose PD Effect Consistent with Dual IgE Neutralization and Down-regulation of Synthesis COHORT 1 (0.2 mg/kg) COHORT 2 (0.6 mg/kg) COHORT 3 (2 mg/kg) 106 1.2 50 106 1.2 50 106 1.2 50 Serum conc. (ng/mL) 15 15 15 Serum conc. (ng/mL) Serum conc. (ng/mL) 10 40 10 40 10
Slide 11: Potential for a Significant Value Inflection with Phase 2 CSU Study
Potential for a Significant Value Inflection with Phase 2 CSU Study Results in 2H26 Phase 2 CSU Study Design N = 145 Phase 2 Study in China CUE-221 High dose Q4W SC with placebo and active comparator (Ascendant CUE-221 Medium dose Q4W SC Randomization CSU Study) Screening Follow up CUE-221 Low dose